Iovance Biotherapeutics: UBS lifts price target to $7, keeps Neutral
UBS analyst David Dai raised Iovance Biotherapeutics’ price target to $7 from $4 and maintained a Neutral rating after reporting Amtagvi revenue of $91M (+52% QoQ) and gross margin at 56%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.